Feature
Nature Biotechnology 25, 179 - 184 (2007)
doi:10.1038/nbt0207-179
Turning biodefense dollars into products
Melanie C Trull1, Tracey V du Laney1 & Mark D Dibner1
Abstract
Five years after the US anthrax attacks, and more than two years after BioShield legislation was ratified, a survey reveals that biodefense funding has thus far produced only a handful of products for clinical development.
- BioAbility, LLC, PO Box 14569, Research Triangle Park, North Carolina 27709, USA. e-mail: mtrull@bioability.com
